中国经济网北京2月26日讯 南新制药(688189.SH)近日发布2025年年度业绩预亏公告。 2022年7月16日，南新制药披露2021年年度权益分派实施公告，以方案实施前的公司总股本140,000,000 股为基数，以资本公积金向全体股东每股转增0.4股，共计转增56,000,000股，本次分配后总股本为 196,000,000股。股权登记日为2022年7月21日，除权（息）日为2022年7月22日。 2023年6月7日，南新制药披露2022年年度权益分派实施公告，以方案实施前的公司总股本196,000,000股 为基数，以资本公积金向全体股东每股转增0.4股，共计转增78,400,000股，本次分配后总股本为 274,400,000股。股权登记日为2023年6月12日，除权（息）日为2023年6月13日。 (责任编辑：马欣) 南新制药于2020年3月26日在上交所科创板上市，发行价格为34.94元/股，首次公开发行新股3500万 股，保荐机构（主承销商）为西部证券股份有限公司，保荐代表人为李锋、邹扬。该股目前处于破发状 态。 南新制药首次公开发行股票募集资金总额为12.23亿元，募集资金净额为11.35 ...

Core Viewpoint - Nanjing Pharmaceutical is attempting to alleviate operational pressure by transferring part of its accounts receivable through public listing, amidst ongoing losses and challenges in transformation and internal control [1][3]. Group 1: Financial Operations - The company plans to transfer accounts receivable totaling 48.98 million yuan, with a book value of 2.99 million yuan after accounting for bad debt provisions of 45.98 million yuan [2]. - Nanjing Pharmaceutical has been in a continuous loss state since its IPO in 2020, with revenues declining from 1.03 billion yuan in 2020 to 263 million yuan in 2024, and a net profit loss of 357 million yuan in 2024 [3][4]. Group 2: Product Challenges - The core product, Peramivir Sodium Injection, which accounted for 73.5% of revenue in 2020, has faced increased competition after its market protection period expired in 2018, leading to a 43.51% price reduction in 2023 [4]. - The company has not disclosed sales revenue for Peramivir since 2020, indicating a significant decline in its market position [4]. Group 3: Acquisition Attempts - Nanjing Pharmaceutical attempted to acquire assets from Future Pharmaceuticals for up to 480 million yuan to diversify its product line, but the deal was terminated due to disagreements on key terms [6][7]. Group 4: Financial and Regulatory Challenges - The company faces increasing financial pressure, with total assets of 1.034 billion yuan and liabilities of 233 million yuan, resulting in a debt ratio of 22.57% [8]. - Nanjing Pharmaceutical is under investigation by the China Securities Regulatory Commission for alleged violations in annual report disclosures, further complicating its financial situation [8].

Group 1 - The company held its first extraordinary general meeting of shareholders on February 11, 2026, in Guangzhou, with no resolutions being rejected [2] - The meeting was convened by the board of directors and chaired by Mr. Zhang Shixi, using a combination of on-site and online voting methods, complying with relevant laws and regulations [2][3] - The company successfully elected independent directors to the second board of directors during the meeting [4][5] Group 2 - Mr. Zhang Shixi submitted his resignation as general manager due to work adjustments, effective immediately upon delivery to the board [9] - The board appointed Mr. Chen Jianxu as the new general manager, with a term lasting until the end of the current board's term [9][12] - Mr. Chen Jianxu has a background in the pharmaceutical industry and has held various positions in reputable companies, ensuring his qualifications meet legal and regulatory requirements [13][14] Group 3 - The company plans to publicly transfer part of its accounts receivable held by a subsidiary through the Hunan United Property Exchange [15][16] - The total accounts receivable to be transferred amounts to 489.784 million yuan, with a provision for bad debts of 459.7945 million yuan, resulting in a book value of 29.9895 million yuan [17][20] - The transaction aims to optimize the company's asset structure and improve liquidity, with the final transaction price to be determined through public bidding [27][24]

（编辑 丛可心） 证券日报网讯 2月11日，南新制药发布公告称，公司董事会于近日收到张世喜先生提交的书面辞职报 告，张世喜先生因工作调整原因申请辞去公司总经理职务。公司于2026年2月11日召开第二届董事会第 二十二次会议，审议通过了《关于聘任公司总经理的议案》，同意聘任陈健旭先生担任公司总经理，任 期自本次董事会审议通过之日起至第二届董事会任期届满之日止。 ...

南新制药表示，为优化公司资产结构，进一步降低应收账款管理成本，提高资产运营质量，提升资产流 动性及保障资金安全，公司拟通过公开挂牌方式转让子公司部分应收账款，截至评估基准日2025年9月 30日，本次拟转让的应收账款账面余额合计48978.4万元，已计提坏账准备45979.45万元，账面价值 2998.95万元。本次资产转让能够推动公司实现更好经营发展，有利于维护公司及全体股东的合法权 益。 北京商报讯（记者 丁宁）2月11日晚间，南新制药（688189）发布公告称，公司拟将其子公司持有的部 分应收账款以公开挂牌的形式在湖南省联合产权交易所有限公司进行转让。 ...

Core Viewpoint - The company, Hunan Nanxin Pharmaceutical Co., Ltd., is planning to transfer part of its accounts receivable through public listing to optimize its asset structure, focus on core business, and enhance risk resistance [1][2]. Group 1: Strategic Initiatives - The public listing of accounts receivable aims to reduce management costs associated with receivables, allowing the company to concentrate resources on core development areas and increase investment in innovative drug research [1]. - This initiative is expected to improve the company's asset structure and operational quality by converting stagnant receivables into cash, thereby reducing the proportion of accounts receivable in total assets and transferring credit risk [1]. Group 2: Financial Implications - The transfer of accounts receivable is anticipated to enhance liquidity and security of funds, providing a quick influx of cash to alleviate pressure from capital occupation and mitigate cash flow issues caused by delayed payments [2]. - The company plans to continue optimizing its accounts receivable management system and strengthen its focus on core business and research innovation to create higher value for investors and contribute to industry development [2].

证券代码：688189 证券简称：南新制药 公告编号：2026-008 湖南南新制药股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 2 月 11 日 （二） 股东会召开的地点：广东省广州市黄埔区开源大道 196 号广州南新制药 有限公司 313 会议室 本次股东会由湖南南新制药股份有限公司（以下简称"公司"）董事会召集， 由董事长张世喜先生主持，会议采用现场投票与网络投票相结合的表决方式进行 | 1、出席会议的股东和代理人人数 | 87 | | --- | --- | | 普通股股东人数 | 87 | | 2、出席会议的股东所持有的表决权数量 | 79,509,579 | | 普通股股东所持有表决权数量 | 79,509,579 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 29.3481 | | 普通股股东所持有表决权数量占公司表决权 ...

经公司第二届董事会提名委员会进行任职资格审查后，公司于2026年2月11日召开第二届董事会第二十 二次会议，审议通过了《关于聘任公司总经理的议案》，同意聘任陈健旭先生担任公司总经理，任期自 本次董事会审议通过之日起至第二届董事会任期届满之日止。 格隆汇2月11日丨南新制药（维权）(688189.SH)公布，公司董事会于近日收到张世喜先生提交的书面辞 职报告，张世喜先生因工作调整原因申请辞去公司总经理职务。根据《公司法》《公司章程》的有关规 定，张世喜先生的辞职报告自送达董事会之日起生效。辞职后，张世喜先生仍担任公司董事、董事长、 董事会战略委员会召集人职务。 ...

Core Viewpoint - Nanjing New Pharmaceutical (688189.SH) aims to optimize its asset structure and improve the quality of asset operations by transferring part of its accounts receivable through a public listing [1] Group 1: Asset Transfer Details - The company plans to transfer accounts receivable with a total book balance of 489.784 million yuan as of the assessment benchmark date of September 30, 2025 [1] - Bad debt provisions amount to 459.7945 million yuan, resulting in a book value of 29.9895 million yuan for the receivables being transferred [1] - The asset transfer is expected to enhance the company's operational development and protect the legal rights of the company and all shareholders [1] Group 2: Transaction Process - The transaction will be conducted through a public listing, and no transaction agreement has been signed yet [1] - It is currently unclear whether the transaction will constitute a related party transaction [1] - If the determined buyer through the public listing process is a related party, the company will follow the necessary review procedures for related party transactions [1]

证券代码：688189 证券简称：南新制药 公告编号：2026-009 湖南南新制药股份有限公司 关于聘任总经理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 湖南南新制药股份有限公司（以下简称"公司"）董事会于近日收到张世喜 先生提交的书面辞职报告，张世喜先生因工作调整原因申请辞去公司总经理职务。 根据《公司法》《公司章程》的有关规定，张世喜先生的辞职报告自送达董事会 之日起生效。辞职后，张世喜先生仍担任公司董事、董事长、董事会战略委员会 召集人职务。 相关规定做好交接工作。截至本公告披露日，张世喜先生不存在未履行完毕的公 开承诺。 公司及公司董事会对张世喜先生在任职期间为公司发展作出的贡献表示衷 心感谢！ 二、高级管理人员聘任情况 根据《公司法》《中华人民共和国证券法》《上海证券交易所科创板上市公司 自律监管指引 1 号——规范运作》等法律法规、规范性文件及《公司章程》等有 关规定，经公司第二届董事会提名委员会进行任职资格审查后，公司于 2026 年 2 月 11 日召开第二届董事会第二十二次会 ...